» Articles » PMID: 19155082

The Long-term Follow-up After Idiosyncratic Drug-induced Liver Injury with Jaundice

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2009 Jan 22
PMID 19155082
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Chronic evolution after drug-induced liver injury (DILI) has been reported. How often this leads to liver-related morbidity and mortality is unexplored.

Methods: Patients who survived DILI and concomitant jaundice reported to the Swedish Adverse Drug Reaction Advisory Committee (1970-2004) were linked to the Swedish Hospital Discharge and Cause of Death Registries.

Results: Among the 712 survivors, 27 could not be retrieved but 685 patients could be linked to the registries, 392 females (57.2%) and 293 males (42.8%) median age 58 (41-74), a mean follow-up of 10 years. A total of 23/685 (3.4%) patients had been hospitalized for liver disease and 5 had liver-related mortality. Eight patients developed cirrhosis (7 decompensated, 5 died), 5 had "cryptogenic" cirrhosis in which DILI might have played a role in this development. Duration of therapy before DILI was longer in patients with liver-related morbidity/mortality (135+/-31 days vs. 53+/-3; p<0.0001). Autoimmune hepatitis developed in 5/23 (22%), all of female gender after a mean of 5.8 years.

Conclusions: Development of clinically important liver disease after severe DILI associated with jaundice is rare after acute DILI. However decompensated "cryptogenic" cirrhosis developed in some patients with fatal outcome in which DILI might have played a role in this development.

Citing Articles

Association of Liver Biomarkers With Jaundice in Patients With Gastrointestinal Complications: An Observational Retrospective Cohort Study.

Raza M, Mustafa A, Amir M, Khurram Saleem M, Ishtiaq H, Akbar A Cureus. 2024; 16(12):e75583.

PMID: 39669649 PMC: 11637320. DOI: 10.7759/cureus.75583.


Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis.

Moreno-Torres M, Quintas G, Martinez-Sena T, Jover R, Castell J Int J Mol Sci. 2024; 25(5).

PMID: 38474249 PMC: 10932304. DOI: 10.3390/ijms25053003.


Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study.

Chung Y, Morrison M, Zen Y, Heneghan M United European Gastroenterol J. 2023; 12(1):66-75.

PMID: 38041550 PMC: 10859714. DOI: 10.1002/ueg2.12499.


Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury.

Fu H, Shen Z, Lai R, Zhou T, Huang Y, Zhao S Hepatol Int. 2023; 17(6):1626-1636.

PMID: 37188998 DOI: 10.1007/s12072-023-10539-4.


Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Andrade R, Aithal G, de Boer Y, Liberal R, Gerbes A, Regev A J Hepatol. 2023; 79(3):853-866.

PMID: 37164270 PMC: 10735171. DOI: 10.1016/j.jhep.2023.04.033.